Methods of reducing mammographic breast density and/or breast cancer risk

A method of reducing mammographic breast density and/or breast stiffness in a patient, comprising administering to the patient:

• i) an effective amount of a selective androgen receptor modulator selected from the group consisting of:
• (2S)-3-(4-cyanophenoxy)-N-[4-cyano-3-(trifluoromethyl)phenyl]-2-hydroxy-2-methylpropanamide;
• (7R,7aS)-2-Chloro-4-(7-hydroxy-1,3-dioxotetrahydropyrrolo[1,2-c]imidazol-2-yl)-3-methylbenzonitrile;
• 4-((R)-2-((R)-2,2,2-trifluoro-1-hydroxyethyl)pyrrolidin-1-yl)-2-trifluoromethyl)benzonitrile;
• 4-(3-Hydroxy-8-aza-bicyclo[3.2.1]octyl)-naphthalene-1-carbonitrile;
• JNJ-28330835;
• 6-(bis-(2,2,2-trifluoroethyl)amino)-4-trifluoromethyl-1H-quinolin-2-one;
• 9-chloro-2-ethyl-1-methyl-3-(2,2,2-trifluoroethyl)-3H-pyrrolo[3,2-f]quinolin-7(6H)-one;
• 2-[4-(dimethylamino)-6-nitro-1,2,3,4-tetrahydroquinolin-2-yl]-2-methylpropan-1-ol;
• and
• (2S)—N-(4-cyano-3-trifluoromethylphenyl)-3-(3-fluoro-4-chlorophenoxy)-2-hydroxy-2-methyl-propanamide;
• or pharmaceutically acceptable salts thereof;
• and
• ii) an effective amount of an aromatase inhibitor selected from the group consisting of:
• exemestane, formestane, anastrozole, letrozole, vorozole, and fadrozole.